Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma announces marketing approval in Japan for XTANDI capsules


Monday, 24 Mar 2014 02:00am EDT 

Astellas Pharma Inc:Obtained marketing approval of oral androgen receptor signaling inhibitor, XTANDI capsules 40mg for the treatment of patients with castration-resistant prostate cancer in Japan.XTANDI is a once-daily, oral androgen receptor signaling inhibitor, which inhibits multiple steps in the androgen receptor signaling pathway, which has been shown to decrease cancer cell growth and can induce cancer cell death (apoptosis). 

Company Quote

1707.0
9.5 +0.56%
28 Nov 2014